NRXP
NRx Pharmaceuticals, Inc. [NRXP] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
NRXP Stock Summary
Top 10 Correlated Stocks
NRXP
In the News
NRx Pharmaceuticals (NRXP) Upgraded to Strong Buy: Here's What You Should Know
NRx Pharmaceuticals (NRXP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
New Strong Buy Stocks for April 4th
DELL, NRXP, STEP, TCOM and PARAA have been added to the Zacks Rank #1 (Strong Buy) List on April 4, 2023.
NRX Pharmaceuticals, Inc. (NRXP) Q4 2023 Earnings Call Transcript
NRX Pharmaceuticals, Inc. (NRXP) Q4 2023 Earnings Call Transcript
NRx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Corporate Update on March 28, 2024
RADNOR, Pa., March 21, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its fourth quarter and full year 2023 financial results after the market closes on Thursday, March 28, 2024, via press release, which will be available on the Company's website at https://ir.nrxpharma.com/press-releases.
Why Is NRX Pharmaceuticals (NRXP) Stock Down 23% Today?
NRX Pharmaceuticals (NASDAQ: NRXP ) stock is falling on Tuesday after the clinical-stage pharmaceutical company announced a proposed public offering for its shares. We still don't know the finer details of the public offering.
NRx Pharmaceuticals (Nasdaq: NRXP) to Present Keynote Address on Ketamine Efficacy and Risks at Upcoming Sachs Neuroscience Innovation Forum in San Francisco
The benefits of ketamine are clear, but so are the risks Ketamine has now demonstrated clear superiority to placebo and non-inferiority to electroshock therapy in randomized trials encompassing more than 1,000 patients NRx to file a New Drug Application for ketamine to treat suicidal depression in 2024 in US and EU RADNOR, Pa. , Jan. 2, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", (NRx), a clinical-stage biopharmaceutical company today announced that it has been selected to give the keynote address entitled "Ketamine for Suicidal Depression: The Benefits are Clear, But So are the Risks," at the upcoming Sachs Neuroscience Innovation Forum in San Francisco, CA on January 7, 2024.
Pick These Top-Ranked Stocks to Deck Up Your Christmas Tree
We have crafted a tree with the most flourishing stocks of 2023 and the ones that are poised to soar in 2024.
5 Biotech stocks tapping into unmet mental health treatment needs
Anyone who has dealt with a mental illness or has a loved one who struggles with a mental illness knows how devastating these diseases are. However, a growing number of biotechnology companies are giving patients new hope for recovery and the ability to thrive.
3 Penny Stocks Under $3 To Watch Right Now
As an aggressive subset of equities, penny stocks offer patient investors occasional lottery ticket-like returns. However, the market gyrations around news and events also invite risk.
NRX Pharmaceuticals, Inc. (NRXP) Q3 2023 Earnings Call Transcript
NRX Pharmaceuticals, Inc. (NASDAQ:NRXP ) Q3 2023 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Matthew Duffy - Chief Business Officer Stephen Willard - Chief Executive Officer Jonathan Javitt - Founder & Chief Scientist Richard Narido - Chief Financial Officer & Treasurer Conference Call Participants Ed Woo - Ascendiant Capital Operator Thank you for standing by. This is the conference operator.
NRXP Financial details
NRXP Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | 0.8 | -0.36 | -1.53 | -0.54 | -3.98 | |
| Operating cash flow per share | -1.56 | -0.07 | -0.8 | -0.6 | -2.86 | |
| Free cash flow per share | -1.56 | -0.07 | -0.8 | -0.6 | -2.86 | |
| Cash per share | 62.9 | 0.23 | 0.59 | 0.3 | 0.61 | |
| Book value per share | 57.98 | -1.28 | 0.44 | 0.11 | -1.55 | |
| Tangible book value per share | 57.98 | -1.28 | 0.44 | 0.11 | -1.55 | |
| Share holders equity per share | 57.98 | -1.28 | 0.44 | 0.11 | -1.55 | |
| Interest debt per share | 3.84 | 0.02 | 0.01 | 0.09 | 1.23 | |
| Market cap | 53.94M | 8.36B | 2.24B | 730.01M | 34.85M | |
| Enterprise value | 55.89M | 8.36B | 2.22B | 720.48M | 39.42M | |
| P/E ratio | 132.06 | -677.26 | -31.27 | -20.72 | -1.16 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -68.04 | -3.69K | -59.48 | -18.36 | -1.61 | |
| PFCF ratio | -68.04 | -3.69K | -59.47 | -18.36 | -1.61 | |
| P/B Ratio | 1.83 | -191.04 | 107.79 | 98.53 | -2.97 | |
| PTB ratio | 1.83 | -191.04 | 107.79 | 98.53 | -2.97 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -8.92K | -162.71 | -19.13 | -16.14 | -1.43 | |
| EV to operating cash flow | -70.5 | -3.69K | -58.76 | -18.12 | -1.82 | |
| EV to free cash flow | -70.5 | -3.69K | -58.75 | -18.12 | -1.82 | |
| Earnings yield | 0.01 | 0 | -0.03 | -0.05 | -0.87 | |
| Free cash flow yield | -0.01 | 0 | -0.02 | -0.05 | -0.62 | |
| Debt to equity | 0.07 | -0.02 | 0.02 | 1.42 | -0.78 | |
| Debt to assets | 0.06 | 0.27 | 0.02 | 0.41 | 1.25 | |
| Net debt to EBITDA | -311.66 | 0.02 | 0.23 | 0.21 | -0.17 | |
| Current ratio | 0.11 | 0.06 | 2.74 | 1.56 | 0.36 | |
| Interest coverage | 0 | -917.63 | -6.43K | 9.69 | -229.89 | |
| Income quality | -1.94 | 0.04 | 0.41 | 1 | 0.72 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -4.14 | -1 | -3.5 | -2.5 | -0.6 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 32.36 | 3.22 | 3.91 | 1.17 | 11.78 | |
| ROIC | 0 | 0.29 | -4.18 | -2.19 | 10.73 | |
| Return on tangible assets | 0.01 | -4.2 | -2.19 | -1.36 | -4.12 | |
| Graham Net | 57.84 | -1.11 | 0.33 | 0.03 | -1.91 | |
| Working capital | -552.95K | -43.23M | 20.79M | 9.21M | -12.16M | |
| Tangible asset value | 29.5M | -43.77M | 20.81M | 7.41M | -11.73M | |
| Net current asset value | -2.5M | -43.78M | 20.79M | 7.39M | -12.16M | |
| Invested capital | 0.07 | -0.02 | 0.02 | 1.42 | -0.78 | |
| Average receivables | 0 | 415.5K | 415.5K | 3.5K | 6.5K | |
| Average payables | 586.77K | 1.89M | 3.42M | 2.88M | 3.35M | |
| Average inventory | 0 | 107K | 107K | -3.5K | -6.5K | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 1.27K | 672.88K | 189.44K | 338.14K | |
| Days of inventory on hand | 0 | 86.08 | 0 | -638.75 | -438 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0.29 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 4.24 | 0 | -0.57 | -0.83 | |
| ROE | 0.01 | 0.28 | -3.45 | -4.76 | 2.57 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.09 | -0.19 | -0.12 | -0.07 | -0.05 | |
| Operating cash flow per share | -0.13 | -0.09 | -0.11 | -0.06 | -0.04 | |
| Free cash flow per share | -0.13 | -0.09 | -0.11 | -0.06 | -0.04 | |
| Cash per share | 0.3 | 0.24 | 0.2 | 0.11 | 0.05 | |
| Book value per share | 0.11 | 0 | -0.04 | -0.08 | -0.14 | |
| Tangible book value per share | 0.11 | 0 | -0.04 | -0.08 | -0.14 | |
| Share holders equity per share | 0.11 | 0 | -0.04 | -0.08 | -0.14 | |
| Interest debt per share | 0.16 | 0.2 | 0.17 | 0.12 | 0.11 | |
| Market cap | 737.61M | 444.52M | 354.39M | 213.06M | 386.03M | |
| Enterprise value | 728.08M | 440.2M | 352.12M | 214.23M | 390.6M | |
| P/E ratio | -32.23 | -8.79 | -10.16 | -8.79 | -22.28 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -88.68 | -73 | -45.37 | -46.68 | -120.94 | |
| PFCF ratio | -88.69 | -72.96 | -45.38 | -46.66 | -121.09 | |
| P/B Ratio | 99.56 | -1.57K | -126.21 | -34.27 | -32.9 | |
| PTB ratio | 99.56 | -1.57K | -126.21 | -34.27 | -32.9 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -70.95 | -39.84 | -43.78 | -37.67 | -88.67 | |
| EV to operating cash flow | -87.53 | -72.29 | -45.07 | -46.94 | -122.37 | |
| EV to free cash flow | -87.54 | -72.25 | -45.09 | -46.92 | -122.52 | |
| Earnings yield | -0.01 | -0.03 | -0.02 | -0.03 | -0.01 | |
| Free cash flow yield | -0.01 | -0.01 | -0.02 | -0.02 | -0.01 | |
| Debt to equity | 1.42 | -42.92 | -4.52 | -1.62 | -0.78 | |
| Debt to assets | 0.41 | 0.56 | 0.64 | 0.77 | 1.25 | |
| Net debt to EBITDA | 0.93 | 0.39 | 0.28 | -0.21 | -1.04 | |
| Current ratio | 1.66 | 0.99 | 0.87 | 0.68 | 0.36 | |
| Interest coverage | 3.3K | -5.88 | 0 | -145.2 | -55.08 | |
| Income quality | 0.81 | 0.55 | 0.9 | 0.75 | 0.74 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 1 | -4 | 2 | -1 | 4 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0.46 | 0.13 | 0.32 | 0.36 | 0.4 | |
| ROIC | -0.31 | -0.91 | -0.8 | -1.52 | 1.71 | |
| Return on tangible assets | -0.22 | -0.58 | -0.44 | -0.46 | -0.59 | |
| Graham Net | 0.02 | -0.08 | -0.1 | -0.13 | -0.17 | |
| Working capital | 10.21M | -308K | -2.83M | -6.24M | -12.16M | |
| Tangible asset value | 7.41M | -284K | -2.81M | -6.22M | -11.73M | |
| Net current asset value | 7.39M | -308K | -2.83M | -6.24M | -12.16M | |
| Invested capital | 1.42 | -42.92 | -4.52 | -1.62 | -0.78 | |
| Average receivables | 277K | 6.5K | 6K | 6K | 6K | |
| Average payables | 2.12M | 2.93M | 2.99M | 2.92M | 4.13M | |
| Average inventory | -277K | -6.5K | -6K | -3K | -3K | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 186.84K | 339.84K | 198.45K | 163.4K | 416.88K | |
| Days of inventory on hand | -630 | -540 | -540 | 0 | -540 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | -0.14 | -0.17 | -0.17 | 0 | -0.17 | |
| ROE | -0.77 | 44.52 | 3.1 | 0.98 | 0.37 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
NRXP Frequently Asked Questions
What is NRx Pharmaceuticals, Inc. stock symbol ?
NRx Pharmaceuticals, Inc. is a US stock , located in Wilmington of De and trading under the symbol NRXP
What is NRx Pharmaceuticals, Inc. stock quote today ?
NRx Pharmaceuticals, Inc. stock price is $4.2798 today.
Is NRx Pharmaceuticals, Inc. stock public?
Yes, NRx Pharmaceuticals, Inc. is a publicly traded company.
Company Profile
- Volume Average 172.16K
- Market Capitalization 49M
- Employee 2
- CEO Mr. Stephen H. Willard Esq.
- Headquarters Wilmington,DE,US
- IPO Date 2017-12-04
-
Website
https://www.nrxpharma.com 
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
